Volume 14, Issue 1 (2026) pp. 72-89 **DOI**: 10.48309/IJABBR.2026.2062050.1616

Review Article

Autoimmune Mechanisms and Treatment Approaches in Graves' Disease-Induced Hyperthyroidism: A Comprehensive Review

Micheal Abimbola Oladosu[1,*] | Moses Adondua Abah[2] | Princewill Chigozie Chijioke[2] | Collins Uchenna Ojukwu[3] | Grace Toluwalogo Balogun[4] | Charles Uforo[5] | Abdullateef Morakinyo Busari[6] | Florence Nkemehule[7] | Abayomi Victor Jemiseye[8] | Ikedionwu Onyinye Ifeoma[8] | Olaide Ayokunmi Oladosu[9] | Ikechukwu Emmanuel Umeh[10]

[1] Department of Biochemistry, Faculty of Basic Medical Sciences, University of Lagos, Idi-Araba, Nigeria

[2]Department of Biochemistry, Faculty of Biosciences, Federal University Wukari, Taraba State, Nigeria

[3] Departments of Medicine, College of Medicine, University of Gullas, Cebu, Philippines

[4] Department of Medicine and Surgery, Faculty of Clinical sciences, University of Ibadan, Ibadan, Nigeria

[5] Department of Medicine and Surgery, College of Medicine, Kursk State Medical University, Kursk City, Russia

[6] Department of Internal Medicine, Internal Medicine and Public Health, Federal Medical Center, Ebute Metta, Lagos, Nigeria

[7]Department of Pharmacognosy, Faculty of Pharmacy, University of Lagos. Idia-Araba, Nigeria

[8]Department of Internal Medicine and Surgery, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria

[9]Department of Computer Science, Faculty of Science and Technology, Babcock University, Ilisan-Remo Ogun State, Nigeria

[10]Department of Microbiology, Faculty of Biological Sciences, University of Nigeria Nsukka, Nsukka, Nigeria

*Corresponding Author E-mail: mikeoladosu@gmail.com

Submitted: 2025-05-29, Revised: 2025-08-07, Accepted: 2025-09-01

Abstract

Graves' disease represents the predominant etiology of hyperthyroidism globally, affecting 60-80% of hyperthyroid cases worldwide. This autoimmune disorder results from thyroid-stimulating immunoglobulins (TSI) inappropriately activating thyroid-stimulating hormone receptors (TSHR), leading to excessive thyroid hormone production and subsequent metabolic dysfunction. The disease predominantly affects women of reproductive age, with a female-to-male ratio of 5-10:1, and exhibits significant geographical variation in prevalence and clinical presentation. This

comprehensive review aims to provide an in-depth analysis of the complex autoimmune mechanisms underlying Graves' disease pathogenesis and critically evaluate current therapeutic modalities alongside emerging treatment strategies that target specific immunological pathways. A systematic literature review was conducted using PubMed, Scopus, and Web of Science databases, focusing on peer-reviewed articles published between 2010 and 2024. Search terms included "Graves' disease," "hyperthyroidism," "autoimmune thyroid," "TSH receptor antibodies," "immunomodulatory therapy," and "thyroid autoimmunity." Articles were screened for relevance and methodological quality. The pathophysiology involves complex molecular interactions between genetic predisposition (HLA-DR3, CTLA-4 polymorphisms), environmental triggers including iodine excess and stress, and immune system dysregulation. CD11c+ B cells have emerged as novel therapeutic targets, demonstrating strong correlation with serum TRAb levels and disease activity markers. Current treatment modalities include antithyroid drugs (methimazole, propylthiouracil), radioiodine therapy, and surgical thyroidectomy. Emerging therapeutic approaches focus on TRAb-targeting strategies, including novel TSHR antagonists (K1-70) and precision medicine strategies that incorporate detailed immunophenotyping profiles. Recent advances in understanding immune mechanisms have opened promising new therapeutic avenues. TRAb-targeted biologics and personalized precision medicine approaches show significant potential for individualized treatment strategies, potentially improving long-term remission rates and substantially reducing disease recurrence in comprehensive Graves' disease management.

Keywords: Graves' disease, Hyperthyroidism, Autoimmune thyroid, TSH receptor antibodies, Immunomodulation, Precision medicine.

Introduction

Graves' disease constitutes the most common cause of hyperthyroidism worldwide, accounting for 60-80% of all hyperthyroid cases [1]. This organ-specific autoimmune disorder demonstrates a marked female predominance, with lifetime risk estimates of 3% in women compared to 0.5% in men [2]. The condition primarily affects women aged 30-50 years and represents a significant public health concern due to its chronicity and potential cardiovascular, ophthalmologic, and dermatological complications. Building upon this epidemiological foundation, the pathogenesis involves the production of thyroid-stimulating immunoglobulins (TSI) that inappropriately activate thyroid-stimulating hormone receptors (TSHR) on thyroid follicular cells, resulting in excessive thyroid hormone production and secretion [3]. This fundamental mechanism underlies all clinical manifestations and therapeutic considerations in the management of Graves' disease. Named after Robert Graves, who first described the condition in the 19th century, the disease encompasses a complex interplay of genetic susceptibility, environmental factors, and immunological dysfunction. Understanding these interconnected mechanisms is crucial for developing targeted therapeutic interventions.

Genetic factors contribute significantly to disease susceptibility, with human leukocyte antigen (HLA) associations, particularly HLA-DR3, and immune regulatory genes such as CTLA-4 and PTPN22 playing crucial roles [4].

These genetic insights directly inform current research into precision medicine approaches and personalized treatment selection.

Environmental triggers including stress, infections, smoking, and iodine exposure may precipitate disease onset or exacerbate clinical progression, creating a multifactorial disease model that requires comprehensive management strategies. The clinical spectrum extends beyond thyrotoxicosis to include extrathyroidal manifestations, most notably Graves' orbitopathy (thyroid eye disease), which affects 25-50% of patients and significantly impacts quality of life [5].

This complexity necessitates multidisciplinary approaches and has driven the development of specialized therapeutic interventions targeting specific disease components. The recent advances in understanding the immunological basis of Graves' disease have identified novel therapeutic targets, including CD11c+ B cells and TRAb-specific pathways [6]. These discoveries, combined with precision medicine approaches that incorporate genetic screening and immunophenotyping, offer promising avenues for personalized treatment strategies that move beyond traditional one-size-fits-all approaches. This review aims to provide a comprehensive analysis of current understanding of autoimmune mechanisms in Graves' disease and critically evaluate both established and emerging therapeutic approaches, with particular emphasis on immunomodulatory interventions and precision medicine strategies. The integration of basic science discoveries with clinical applications represents the central theme throughout this analysis.

Immunological Basis of Graves' Disease

TSH Receptor Antibodies and Pathophysiology

Graves' disease represents a paradigmatic organ-specific autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that target the thyroid-stimulating hormone receptor (TSHR) [7]. Figure 1 shows the pathophysiology of Graves' disease.



Figure 1 Pathophysiology of Graves' disease – molecular mechanisms (Original illustration based on published pathophysiological data [3])

Understanding the molecular basis of this interaction is fundamental to appreciating both disease pathogenesis and therapeutic target identification. TSH

receptor antibodies (TRAb) can be classified into three functional categories: stimulating antibodies (TSI) that mimic TSH action, blocking antibodies that inhibit TSH binding, and neutral antibodies that bind without functional effects [8].

This classification system has direct clinical implications for diagnosis, monitoring, and treatment selection. In Graves' disease, stimulating TRAb predominates, binding to and activating TSHRs on thyroid follicular cells. This activation triggers a G-protein coupled signaling cascade, increasing intracellular cyclic adenosine monophosphate (cAMP) levels, which subsequently enhances iodine uptake, thyroglobulin synthesis and processing, and thyroid hormone release [9]. This unregulated activation constitutes the fundamental mechanism underlying hyperthyroidism in Graves' disease and explains why therapeutic interventions targeting this pathway show particular promise.

This detailed understanding of TRAb subtypes has led to the development of more sophisticated diagnostic approaches and targeted therapeutic strategies, particularly the emerging TRAb-blocking biologics discussed later in this review.

Genetic Predisposition and HLA Associations

Genetic factors account for approximately 79% of Graves' disease susceptibility, with the human leukocyte antigen (HLA) region on chromosome 6p21 showing the strongest associations [10]. These genetic insights are increasingly being translated into clinical risk stratification and personalized treatment approaches. HLA associations demonstrate significant ethnic variation, with different alleles conferring risk or protection in various populations. This ethnic specificity has important implications for global disease management and suggests that personalized medicine approaches may require population-specific modifications. In Caucasian populations, HLA-B08, DR3, and DQA1*05:01* alleles increase Graves' disease susceptibility, while HLA-DRB107:01 provides protective effects [11].

Additional risk-associated alleles include C07:01, DQA105:01, DRB103, and DQB102:01. The haplotype DRB103:01-DQA105:01-DQB1*02:01 (DR17, DQ2) shows the strongest association with disease risk. Table 1 highlights the Classification and significance of TSH receptor Antibodies.

Table 1 Classification and clinical significance of TSH receptor antibodies [9]

TRAb Type	Mechanism of Action	Clinical Significance	Laboratory Detection	Normal Range
Stimulating TSI	Mimics TSH action, activates cAMP pathway	Causes hyperthyroidism in Graves' disease	TSH bioassay	<140% of baseline
Blocking TRAb	Inhibits TSH binding, blocks activation	May cause hypothyroidism	TSH bioassay	<10% inhibition
Neutral TRAb	Binds without functional effect	Uncertain clinical relevance	TRAb immunoassay	<1.75 IU/L
Total TRAb	All antibodies binding TSHR	Disease monitoring and diagnosis	Competitive binding assay	<1.75 IU/L

Table 2 HLA associations in Graves' disease across different populations [4,10,11]

Population	Risk Associated Alleles	Protective Alleles	Odds Ratio (95% CI)	Ref.
Caucasian	HLA-B*08, DR3, DQA1*05:01	HLA-DRB1*07:01	2.8 (2.1-3.7)	[10,11]
Han Chinese	HLA-DPB1*05:01	HLA-B*54:01	1.9 (1.4-2.6)	[12]
Japanese	HLA-B*38:02, DRB1*16:02	HLA-DRB1*08:02	2.1 (1.5-2.9)	[12]
Korean	HLA-DQA1*01:02, DQB1*05:02	HLA-A*02:07	1.8 (1.2-2.7)	[12]

Asian populations demonstrate different HLA associations, with HLA-B38:02, DRB116:02, DQA101:02, and DQB105:02 correlating with increased Graves' orbitopathy risk, while HLA-B54:01 may confer protection [12]. The HLA-DPB105:01 allele has been identified as a significant genetic determinant in Han Chinese populations (See Table 2).

Beyond HLA associations, polymorphisms in PTPN22, CTLA-4, TSHR, IL-21, and KREC genes influence disease susceptibility and treatment response [13]. These genetic insights support the development of risk stratification tools and personalized therapeutic approaches, representing a significant advancement over traditional empirical treatment selection.

Role of B Cells, T Cells, and Cytokines

Recent research has identified CD11c+ B cells as crucial mediators in Graves' disease pathogenesis (As shown in Figure 2) [14].

This discovery represents a significant advancement in understanding disease mechanisms and has opened new therapeutic avenues. These specialized B cells are expanded in patients with Graves' disease, with circulating levels correlating with serum TRAb concentrations. CD11c+ B cells can differentiate into antibody-secreting cells that produce TRAb and secrete various cytokines including pro-inflammatory mediators (IL-1β, IL-6, IL-17A, IFN-γ, and IL-9) and chemokines (IL-8, CXCL10, RANTES, MIP-1α/β, and MCP-1). This dual function as both antibody producers and inflammatory mediators makes them particularly attractive therapeutic targets.



Figure 2 CD11c+ B cells in Graves' disease pathogenesis (adapted with permission from Cao *et al.* [6])

T lymphocytes play essential roles in disease initiation and perpetuation, with their understanding evolving significantly over recent years. While initially considered a Th2-mediated process, current evidence reveals complex involvement of both Th1 and Th2 responses [15]. Th1 cells produce interferon-gamma (IFN-γ), promoting IgG1 synthesis, the predominant TRAb subclass responsible for thyroid stimulation. Th17 cells and regulatory T cells (Treg) imbalances further contribute to autoimmune pathogenesis [16]. Dendritic cells (DCs) serve as critical antigen-presenting cells, found in increased numbers within thyroid tissue

of Graves' disease patients. These cells facilitate T cell activation by presenting thyroid antigens, perpetuating the autoimmune response [17]. The interaction between DCs, T cells, and B cells creates a self-perpetuating inflammatory cycle that maintains disease activity and explains the chronic nature of Graves' disease. This comprehensive understanding of immune cell interactions has informed the development of targeted immunotherapies and provides the scientific rationale for emerging precision medicine approaches in Graves' disease management.

Clinical Manifestations and Diagnosis

Systemic Manifestations

Graves' disease presents with diverse clinical manifestations reflecting thyroid hormone excess and autoimmune tissue involvement. Understanding this clinical spectrum is essential for appropriate diagnosis and management planning. The classic triad includes hyperthyroidism, goiter, and ophthalmopathy, though the complete syndrome occurs in only a subset of patients, highlighting the disease's clinical heterogeneity. Cardiovascular effects predominate in many patients, including palpitations, tachycardia, systolic hypertension, and atrial fibrillation, particularly in elderly individuals [18]. These manifestations may constitute the presenting symptoms and are generally reversible with appropriate hyperthyroidism treatment, though early recognition and management are crucial to prevent long-term complications. The characteristic diffuse, non-tender, vascular goiter results from TSHR-induced thyroid follicular cell hyperplasia. An audible thyroid bruit may be present due to increased thyroid blood flow. Compressive symptoms including dysphagia or dyspnea may occur with larger goiters, necessitating careful evaluation and potentially surgical intervention. Figure 3 highlights the Clinical manifestations and Diagnostic Algorithm.



Figure 3 Clinical manifestations and diagnostic algorithm (original illustration based on clinical guidelines [18-20])

The comprehensive diagnostic algorithm for Graves' disease shows clinical presentation, biochemical testing sequences, and imaging studies. The algorithm includes differential diagnosis considerations and management decision points based on TRAb status and clinical severity.

Graves' Orbitopathy

Graves' orbitopathy (GO), affecting 25-50% of patients, represents the most significant extrathyroidal manifestation [19]. This condition results from

autoimmune inflammation of extraocular muscles, retro-orbital fibroblasts, and adipose tissue, creating a complex management challenge that often requires specialized multidisciplinary care. Clinical features include proptosis (exophthalmos), periorbital edema, diplopia, ocular discomfort, and in severe cases, optic nerve compression leading to vision loss. The severity of ophthalmopathy does not consistently correlate with the degree of hyperthyroidism, and GO may precede, accompany, or follow thyroid dysfunction. This temporal variability necessitates ongoing ophthalmologic monitoring regardless of thyroid status.

The condition significantly impacts quality of life and requires specialized multidisciplinary management involving endocrinologists, ophthalmologists, and often plastic surgeons for comprehensive care.

Dermatological Manifestations

Pretibial myxedema, occurring in less than 5% of patients, represents a pathognomonic but rare manifestation characterized by localized non-pitting edema and skin thickening on the anterior shins [20]. This condition results from glycosaminoglycan accumulation induced by TSHR antibodies and frequently accompanies severe ophthalmopathy, suggesting shared pathogenic mechanisms.

Diagnostic Approach

Diagnosis relies on clinical assessment, biochemical testing, and imaging studies, with the integration of these approaches providing comprehensive disease characterization. Biochemical evaluation reveals elevated free T4 and T3 levels with suppressed TSH. Positive TRAb or TSI confirms the diagnosis and distinguishes Graves' disease from other causes of hyperthyroidism, making antibody testing essential for accurate diagnosis.

The diagnostic workup should include:

Disease activity monitoring: TRAb levels for treatment response assessment,

Treatment response prediction: Baseline TRAb concentrations help predict remission likelihood.

Relapse risk assessment: Persistently elevated TRAb indicates higher recurrence risk.

Pregnancy monitoring: For assessment of fetal/neonatal thyroid effects.

Table 3 Clinical activity score (CAS) for Graves' orbitopathy assessment [19]

Clinical Feature	Points	Assessment Method
Spontaneous orbital pain	1	Patient-reported, Present/absent
Gaze-evoked orbital pain	1	Assessed during eye movement
Eyelid erythema	1	Clinical examination
Eyelid oedema	1	Clinical examination
Conjunctival redness	1	Slit-lamp examination
Chemosis	1	Clinical examination
Caruncle swelling	1	Clinical examination
Total CAS Score	**0-7**	**Active GO if ≥ 3/7**

Severity Classification:
Mild GO: CAS <3, No diplopia, Proptosis <3 mm above normal
Moderate-severe GO: CAS ≥3, Diplopia, or Proptosis ≥3 mm above normal

Imaging modalities include radioactive iodine uptake (RAIU) scan showing diffuse increased uptake, and thyroid ultrasound with Doppler demonstrating hypervascularity ("thyroid inferno").

For patients with ophthalmopathy, orbital MRI or CT can confirm extraocular muscle enlargement and assess disease severity, providing crucial information for treatment planning. Table 3 illustrates the Clinical Activity Scores (CAS).

Current Treatment Strategies

Antithyroid Drugs

Antithyroid drugs (ATDs) represent the preferred initial therapy for most patients with Graves' disease, reflecting their established efficacy and generally manageable side effect profile. Methimazole and carbimazole are considered first-line agents due to their longer half-lives and superior efficacy profiles compared to propylthiouracil (PTU) [21]. These medications inhibit thyroid hormone synthesis by blocking thyroid peroxidase activity, directly addressing the fundamental pathophysiologic mechanism. PTU offers additional benefits through inhibition of peripheral T4 to T3 conversion and demonstrates lower placental transfer, making it preferred during pregnancy's the first trimester and in thyrotoxic crises [22]. This specific indication reflects the drug's unique pharmacologic properties and safety profile in vulnerable populations. The standard treatment duration ranges from 12 to 18 months, with remission rates varying from 30 to 70% following therapy discontinuation. Extended ATD therapy beyond 60 months may achieve higher remission rates, with some studies reporting 85% remission at 4 years [23]. The European Thyroid Association recommends 18-month treatment duration for adults and 36 months for children, typically initiating with methimazole or carbimazole.

Table 4 Comparative efficacy and safety profiles of the current treatments

Treatment	Remission Rate	Time to Euthyroidism	Major Adverse Effects	Contraindications	Ref.
Methimazole	30-70% at 18 months	4-8 weeks	Agranulocytosis (0.1-0.5%), hepatotoxicity	Pregnancy (The 1st Trimester)	[21,24,41]
Propylthiouracil	30-60% at 18 months	6-10 weeks	Severe hepatotoxicity (0.1%), ANCA vasculitis	Generally avoided as first-line	[22,24,42]
Radioiodine	90-95% permanent cure	2-6 months	Hypothyroidism (80-90%), GO worsening	Pregnancy, breastfeeding, active GO	[25,26,43]
Thyroidectomy	100% immediate cure	Immediate	Hypoparathyroidism (1-3%), RLN injury (1-2%)	High surgical risk	[28,44,45]

GO = Graves' orbitopathy; RLN = Recurrent laryngeal nerve; and ANCA = Anti-neutrophil cytoplasmic antibodies.



Figure 4 Treatment decision tree for Graves' disease (original algorithm based on clinical guidelines [21,27,40])

ATD therapy carries risks of rare but serious adverse effects, including agranulocytosis, hepatotoxicity, ANCA-positive vasculitis, and pancreatitis [24]. High recurrence rates following therapy discontinuation represent a significant limitation that has driven research into predictive biomarkers and alternative therapeutic approaches. Beta-blockers provide symptomatic relief for tachycardia, tremors, and anxiety during initial treatment phases. Table 4 shows the Comparative Efficacy and the safety profiles of the current treatments. Evidence-based treatment algorithm for Graves' disease management. Decision points include patient age, pregnancy status, goiter size, TRAb levels, and presence of orbitopathy. The algorithm incorporates first-line therapy selection, monitoring parameters, and definitive treatment timing (As shown in Figure 4).

Radioiodine Therapy

Radioiodine (RAI) therapy offers definitive treatment through thyroid tissue ablation, representing a well-established approach with decades of clinical experience. Patients ingest radioactive iodine, which concentrates in thyroid tissue and gradually destroys thyroid cells through beta-radiation emission [25]. This approach provides permanent resolution of hyperthyroidism but commonly results in hypothyroidism requiring lifelong thyroid hormone replacement. A significant concern involves potential worsening of Graves' orbitopathy, particularly in predisposed patients [26]. Corticosteroid prophylaxis may be indicated for high-risk individuals, though the optimal protocol remains subject to ongoing research. RAI therapy is contraindicated during pregnancy and breastfeeding and is generally avoided in

young children and patients with active moderate-to-severe ophthalmopathy. Recent surveys indicate a decline in RAI use as first-line therapy compared to antithyroid medications, reflecting changing clinical preferences and patient factors [27]. This trend reflects evolving understanding of long-term outcomes and patient quality-of-life considerations.

Surgical Management

Thyroidectomy provides immediate and permanent resolution of hyperthyroidism, offering definitive cure with predictable outcomes. This approach is preferred for patients with large goiters, suspected malignancy, or women planning pregnancy who wish to avoid radioiodine therapy [28]. Total thyroidectomy requires lifelong thyroid hormone replacement therapy but eliminates disease recurrence concerns. Surgical risks include potential complications related to anesthesia, bleeding, infection, hypoparathyroidism, and recurrent laryngeal nerve injury affecting voice function. However, in experienced hands, thyroidectomy demonstrates excellent safety profiles and outcomes, with complication rates comparable to those listed in Table 4.

Immunomodulatory Therapies

For moderate to severe Graves' orbitopathy, immunosuppressive therapy represents the standard approach, addressing the inflammatory component of extrathyroidal manifestations. High-dose intravenous methylprednisolone constitutes first-line treatment for active, inflammatory GO [29]. This therapy aims to reduce orbital inflammation and prevent irreversible fibrotic changes that characterize advanced disease. Teprotumumab, a monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), has emerged as a breakthrough therapy for thyroid eye disease. Clinical trials demonstrate significant reduction in proptosis and diplopia, representing the first FDA-approved medical therapy specifically for Graves' orbitopathy [30]. This approval represents a paradigm shift in GO management from primarily supportive care to targeted therapeutic intervention.

Graves' orbitopathy assessment using clinical activity score (CAS) and severity grading with corresponding treatment algorithms shows progression from active inflammatory phase to fibrotic phase and targeted therapies including corticosteroids, teprotumumab, and surgical interventions. Rituximab, an anti-CD20 monoclonal antibody targeting B cells, shows promise for refractory cases of both hyperthyroidism and orbitopathy, though evidence remains limited to small studies and case series [31]. The targeting of B cells aligns with emerging understanding of CD11c+ B cell roles in disease pathogenesis.

Emerging Therapies and Future Directions

TRAb-Targeting Therapeutics

Novel therapeutic approaches focus on directly targeting the TSH receptor or interfering with TRAb binding, representing a mechanistically driven approach to treatment. Small molecule TSHR antagonists, including ANTAG-3, VA-K-14, and S37a, demonstrate promising preclinical results for directly inhibiting TSHR signaling [32].

These compounds offer potential advantages of oral administration and targeted receptor blockade. TSHR-blocking antibodies, particularly K1-70, represent an innovative approach to competitively inhibit both TSH and stimulating TRAb from activating the TSH receptor. Phase I clinical trials of K1-70 demonstrated significant effects on

thyroid function, inducing hypothyroidism in some patients while improving Graves' orbitopathy with reduced proptosis As Shown in Figure 5 [33].



Figure 5 Graves' orbitopathy severity assessment and management (Source: Original illustration synthesizing orbitopathy management data [5,19,29,30])

These dual effects suggest potential utility for patients with both hyperthyroidism and significant ophthalmopathy. These direct TSHR-targeting approaches offer potential advantages by specifically addressing the fundamental pathophysiology while avoiding broad immunosuppression, potentially reducing adverse effects associated with conventional treatments.

Precision Medicine and Risk Stratification

Advances in genomics and immunophenotyping enable personalized treatment approaches that move beyond traditional empirical therapy selection. Genome-wide association studies (GWAS) and HLA typing facilitate disease susceptibility prediction and may guide therapeutic selection [34]. Genetic screening could identify patients more likely to benefit from immunomodulators versus conventional treatments, optimizing treatment selection and resource allocation.

Predictive biomarker development focuses on TRAb levels, T-cell profiles, and cytokine patterns to predict disease activity, treatment response, and recurrence risk. Integrating these markers into clinical algorithms may optimize follow-up strategies and guide the timing of definitive therapies, moving toward truly personalized medicine. The proposed precision medicine model incorporates immunophenotyping, genetic screening, and TRAb quantification to stratify patients into risk categories. This classification system could recommend personalized

treatment algorithms, including conservative management, immune modulation, or definitive therapy based on individual patient characteristics. Table 5 lists all the Precision medicine biomarkers for risk stratifications.

Table 5 Precision medicine biomarkers for risk stratification [4,6,10,14,36,38]

Biomarker Category	Specific Marker	Clinical Application	Predictive Value
Genetic	HLA-DR3, CTLA-4, PTPN22	Disease susceptibility	OR 2.8-4.2
Immunological	CD11c+ B cells, TRAb levels	Disease activity monitoring	r = 0.78 with TRAb
Biochemical	Free T4/T3 ratio, TSH	Treatment response prediction	85% accuracy
Inflammatory	IL-6, IFN-γ, TNF-α	Disease severity assessment	Correlates with CAS
Ophthalmologic	Orbital MRI, CAS score	GO risk stratification	92% sensitivity

OR = Odds ratio, r = correlation coefficient, and CAS = Clinical Activity Score.

Future Clinical Integration of TRAb-Targeted Biologics

Based on current evidence and ongoing trials, we anticipate the following integration pathway for novel biologics such as K1-70:

Short-term (2-5 years): TRAb-targeted biologics will likely serve as adjunctive therapies for:

Refractory cases unresponsive to conventional treatment,

Patients with severe Graves' orbitopathy, and

Cases requiring rapid TRAb reduction.

Medium-term (5-10 years): These agents may become primary therapy for selected populations based on:

Genetic risk profiling (HLA-DR3 positive patients),

High baseline TRAb levels (>5x upper normal limit), and

Presence of extrathyroidal manifestations.

Cost-effectiveness considerations: Current estimated costs ($50,000-100,000 per treatment course) limit widespread use. However, targeted application in high-risk patients may prove cost-effective by preventing:

Multiple treatment failures,

Surgical complications, and

Long-term disability from orbitopathy.

Long-term outcomes: Phase III trials are needed to establish:

Sustained remission rates,

Safety in long-term use,

Optimal dosing regimens, and

Patient selection criteria.

We anticipate these biologics will eventually be integrated into personalized treatment algorithms rather than replacing conventional therapies entirely.

Clinical Trial Landscape

The current clinical trials reflect a strategic shift toward immune-targeted interventions rather than symptomatic control. Active investigations include anti-TSHR monoclonal antibodies in Phase II trials, rituximab for refractory Graves' orbitopathy in Phase III studies, and TOL-3021, a tolerogenic DNA vaccine targeting HLA-DR, in Phase II development [35].

These trials address the fundamental autoimmune mechanisms while potentially offering improved safety

profiles and reduced recurrence rates compared to conventional therapies (Table 6).

Table 6 Emerging therapeutic targets and current development status [35]

Therapeutic Agent	Target	Mechanism	Development Phase	Key Findings
K1-70	TSHR	Blocking monoclonal antibody	Phase I completed	Reduced TRAb, improved proptosis
Teprotumumab	IGF-1R	Monoclonal antibody	FDA approved	83% proptosis response vs. 10% placebo
Rituximab	CD20+ B cells	B cell depletion	Phase III	Mixed results for GO, limited hyperthyroidism efficacy
TOL-3021	HLA-DR	Tolerogenic DNA vaccine	Phase II	Immune tolerance induction
ANTAG-3	TSHR	Small molecule antagonist	Preclinical	Direct TSHR inhibition

IGF-1R = Insulin-like growth factor-1 receptor and GO = Graves' orbitopathy.

Discussion

This comprehensive review highlights the complex autoimmune mechanisms underlying Graves' disease and the evolving therapeutic landscape. Recent advances in understanding immune pathophysiology have identified novel targets, including CD11c+ B cells and TRAb-specific pathways, offering promising avenues for targeted interventions [36]. The identification of CD11c+ B cells, as both antibody producers and cytokine secretors, addresses fundamental questions regarding translational significance in Graves' disease management. These cells represent viable therapeutic targets, with ongoing research investigating B-cell depletion strategies and specific CD11c+ subset targeting. Current clinical trials with rituximab provide preliminary evidence for B-cell targeting approaches [37]. Regarding emerging therapies, K1-70 has progressed through Phase I trials with encouraging results showing both thyroid function normalization and ophthalmopathy improvement. TOL-3021 remains in Phase II development, with preliminary data suggesting immune tolerance induction. These advances represent significant progress from earlier preclinical stages [38]. The clinical heterogeneity observed in Graves' disease reflects the complex interplay between genetic susceptibility, environmental triggers, and immune system dysregulation. This complexity necessitates personalized approaches that consider individual patient characteristics, including HLA typing, TRAb levels, and disease severity markers. The integration of precision medicine principles into clinical practice represents a significant advancement over traditional empirical treatment approaches. Current evidence suggests that TRAb-targeted biologics such as K1-70 will likely serve as adjunctive therapies initially, particularly for patients with refractory disease or significant ophthalmopathy. Long-term integration into treatment pathways will depend on Phase III trial results, cost-effectiveness analyses, and real-world efficacy data. These agents may eventually become primary therapies for selected patient populations based on genetic and immunological profiles [39]. The evolving understanding of Graves'

disease pathogenesis has revealed multiple potential therapeutic targets beyond the traditional focus on thyroid hormone synthesis inhibition. The recognition that this is fundamentally an autoimmune disorder has shifted research focus toward immune-modulating interventions that address root causes rather than merely managing symptoms. Future research priorities should include validation of precision medicine approaches in larger, diverse patient cohorts, development of cost-effective implementation strategies for emerging biologics, and establishment of long-term safety and efficacy profiles for novel therapeutic agents. The integration of artificial intelligence and machine learning approaches may further enhance risk stratification and treatment selection algorithms.

Conclusion

Graves' disease represents a complex autoimmune disorder with significant clinical heterogeneity and substantial healthcare impact. The disease's multifaceted nature, encompassing thyroid dysfunction, ophthalmopathy, and systemic manifestations, requires comprehensive management approaches that address both immediate symptoms and long-term complications. Recent advances in understanding immune mechanisms have revealed novel therapeutic targets and enabled precision medicine approaches that move beyond traditional one-size-fits-all treatments. CD11c+ B cells, TRAb-targeted therapies, and genetic risk stratification offer promising avenues for personalized treatment strategies that could significantly improve patient outcomes. The evolving therapeutic landscape includes both refinements of conventional approaches and development of innovative immunomodulatory interventions. The approval of teprotumumab for Graves' orbitopathy represents a paradigm shift toward targeted biological therapies, while emerging TRAb-blocking antibodies offer potential for addressing the fundamental pathophysiology directly. Integration of genetic screening, immunophenotyping, and predictive biomarkers may enable personalized treatment selection, potentially improving remission rates while minimizing adverse effects and recurrence risk. This precision medicine approach represents the future direction of Graves' disease management, offering hope for more effective and individualized care. The clinical implementation of these advances will require careful consideration of cost-effectiveness, healthcare infrastructure requirements, and physician education needs. Successful integration of precision medicine approaches will depend on developing streamlined testing protocols and clinical decision-support systems that can be readily implemented in diverse healthcare settings. Future research should focus on validating precision medicine approaches in larger patient cohorts, developing cost-effective implementation strategies, and conducting long-term outcome studies for emerging biologics. Collaborative international research efforts will be essential for generating the evidence base needed to support widespread adoption of these innovative approaches. The ultimate goal remains to achieve sustained remission with minimal treatment-related morbidity through personalized, mechanism-based therapeutic interventions. The convergence of advancing scientific understanding, technological capabilities, and clinical innovation positions the field to make significant strides toward this goal in the coming decade. As we move forward, the integration of basic scientific discoveries with clinical

applications will continue to drive progress in Graves' disease management. Collaboration between researchers, clinicians, and patients will be essential for translating these scientific advances into meaningful improvements in patient care and quality of life.

Abbreviations

ATD: Antithyroid Drugs
CAS: Clinical Activity Score
GO: Graves' Orbitopathy
HLA: Human Leukocyte Antigen
IGF-1R: Insulin-like Growth Factor-1 Receptor
PTU: Propylthiouracil
RAI: Radioiodine Therapy
TRAb: TSH Receptor Antibodies (total)
TSH: Thyroid-Stimulating Hormone
TSHR: Thyroid-Stimulating Hormone Receptor
TSI: Thyroid-Stimulating Immunoglobulins (functional subset of TRAb)

Acknowledgments

The authors would like to thank all the researchers who contributed to the success of this research work. They also acknowledge the valuable contributions of the international research community in advancing our understanding of Graves' disease pathogenesis and treatment approaches.

Conflict of Interest

No conflicts of interest were reported by the authors in this study.

Ethical Considerations

This review article utilized only published literature and did not involve human subjects; therefore, ethical approval was not required. All cited studies were conducted in accordance with appropriate ethical guidelines and institutional review board approvals as reported in the original publications.

Authors' Contributions

Micheal Abimbola Oladosu Conceptualization, Study design, Methodology, Supervision, Writing Original draft. Moses Adondua Abah Data collection, Investigation, Formal analysis, Writing – Review & editing. Princewill Chigozie Chijioke Data acquisition, Validation, Statistical analysis. Collins Uchenna Ojukwu Literature review, Resources, Data curation. Grace Toluwalogo Balogun Draft preparation, Writing – Review & editing. Charles Uforo Visualization, Data interpretation. Abdullateef Morakinyo Busari Critical revision of the manuscript, Validation. Florence Nkemehule Data support, Literature search. Abayomi Victor Jemiseye Methodology, Data analysis. Ikedionwu Onyinye Writing – Review & editing, Proofreading. Olaide Ayokunmi Oladosu Administrative support, Project coordination. Ikechukwu Emmanuel Umeh Statistical analysis, Validation, Review of final manuscript.

Ethics Code

Not applicable.

Funding

No funding was received for this research work.

ORCID

Micheal Abimbola Oladosu
https://orcid.org/0009-0000-5098-1247
Moses Adondua Abah
https://orcid.org/0000-0002-9268-1661
Princewill Chigozie Chijioke
https://orcid.org/0009-0009-1696-0966
Collins Uchenna Ojukwu
https://orcid.org/0009-0003-8769-6791
Grace Toluwalogo Balogun
https://orcid.org/0009-0006-1114-6488
Charles Uforo
https://orcid.org/0009-0000-2825-8335

Abdullateef Morakinyo Busari
https://orcid.org/0009-0009-2265-0569
Florence Nkemehule
https://orcid.org/0000-0002-2833-2053
Abayomi Victor Jemiseye
https://orcid.org/0009-0009-7339-6791
Ikedionwu Onyinye Ifeoma
https://orcid.org/0009-0008-2116-5994
Olaide Ayokunmi Oladosu
https://orcid.org/0009-0001-8550-5598
Ikechukwu Emmanuel Umeh
https://orcid.org/0009-0000-6398-6506

References

[1]. Hussain, Y.S., Hookham, J.C., Allahabadia, A., Balasubramanian, S.P., Epidemiology, management and outcomes of graves' disease—real life data. *Endocrine*, **2017**, 56(3), 568-578.
[2]. Majid, S., Graves' disease: Pathophysiology, genetics and management. *Graves' Disease*, **2021**, 67.
[3]. Pokhrel B, Bhusal K. Graves disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; **2023**.
[4]. Stasiak, M., Stasiak, B., Zawadzka-Starczewska, K., Lewiński, A., Significance of hla in graves' disease and graves' orbitopathy in asian and caucasian populations–a systematic review. *Frontiers in Immunology*, **2023**, 14, 1256922.
[5]. Bartalena, L., Tanda, M.L., Current concepts regarding graves' orbitopathy. *Journal of Internal Medicine*, **2022**, 292(5), 692-716.
[6]. Cao, Y., Zhao, X., You, R., Zhang, Y., Qu, C., Huang, Y., Yu, Y., Gong, Y., Cong, T., Zhao, E., Cd11c+ b cells participate in the pathogenesis of graves' disease by secreting thyroid autoantibodies and cytokines. *Frontiers in Immunology*, **2022**, 13, 836347.
[7]. Diana, T., Olivo, P.D., Kahaly, G.J., Thyrotropin receptor blocking antibodies. *Hormone and Metabolic Research*, **2018**, 50(12), 853-862.
[8]. Kahaly, G.J., Diana, T., Tsh receptor antibody functionality and nomenclature. *Frontiers in Endocrinology*, **2017**, 8, 28.
[9]. Pirahanchi Y, Toro F, Jialal I. Physiology, thyroid stimulating hormone. StatPearls. Treasure Island (FL) **2023**.
-Starczewska, K., Tymoniuk, B., Stasiak, B., Lewiński, A., Stasiak, M., Actual associations between hla haplotype and graves' disease development. *Journal of Clinical Medicine*, **2022**, 11(9), 2492.
[11]. Li, Y., Yao, Y., Yang, M., Shi, L., Li, X., Yang, Y., Zhang, Y., Xiao, C., Association between hla-b* 46 allele and graves disease in asian populations: A meta-analysis. *International Journal of Medical Sciences*, **2013**, 10(2), 164.
[12]. Huang, X., Liu, G., Mei, S., Cai, J., Rao, J., Tang, M., Zhu, T., Chen, W., Peng, S., Wang, Y., Human leucocyte antigen alleles confer susceptibility and progression to graves' ophthalmopathy in a southern chinese population. *British Journal of Ophthalmology*, **2021**, 105(10), 1462-1468.
[13]. Cheung, Y.K., Cheng, S.H., Chan, E.J., Lo, S.V., Ng, M.H., Kwan, P., Hla-b alleles associated with severe cutaneous reactions to antiepileptic drugs in h an c hinese. *Epilepsia*, **2013**, 54(7), 1307-1314.
[14]. Hansen, M., Cheever, A., Weber, K.S., O'Neill, K.L., Characterizing the interplay of lymphocytes in graves' disease. *International Journal of Molecular Sciences*, **2023**, 24(7), 6835.
[15]. Hammad, H., Lambrecht, B.N., The basic immunology of asthma. *Cell*, **2021**, 184(6), 1469-1485.
[16]. Qin, Y., Gao, C., Luo, J., Metabolism characteristics of th17 and regulatory t cells in autoimmune diseases. *Frontiers in Immunology*, **2022**, 13, 828191.
[17]. Bogović Crnčić, T., Girotto, N., Ilić Tomaš, M., Krištofić, I., Klobučar, S., Batičić, L., Ćurko-Cofek, B., Sotošek, V., Innate immunity in autoimmune thyroid disease during pregnancy. *International Journal of Molecular Sciences*, **2023**, 24(20), 15442.
[18]. Yamakawa, H., Kato, T.S., Noh, J.Y., Yuasa, S., Kawamura, A., Fukuda, K., Aizawa, Y., Thyroid hormone plays an important role in cardiac function: From bench to bedside. *Frontiers in physiology*, **2021**, 12, 606931.
[19]. Aoun, T., Danielova Gueorguieva, D., Wu, K.Y., Orbital inflammation in thyroid eye disease: Stress responses and their implications. *Stresses*, **2024**, 4(1), 54-78.
[20]. Van Le, C., Linh, P.N.T., Thi, X.N., Vo, T.T., Pretibial myxedema in grave's disease: A case report and treatment review of the

literature. *Clinical Case Reports*, **2024**, 12(2), e8478.
[21]. Abdi, H., Amouzegar, A., Azizi, F., Antithyroid drugs. *Iranian Journal of Pharmaceutical Research: IJPR*, **2019**, 18(Suppl1), 1.
[22]. Awosika AO, Singh G, Correa R. Methimazole. InStatPearls, **2023**.
[23]. Kim, H.J., Long-term management of graves disease: A narrative review. *Journal of Yeungnam Medical Science*, **2023**, 40(1), 12-22.
[24]. DeGroot LJ. Diagnosis and treatment of Graves' disease. Endotext. South Dartmouth (MA), **2016**.
[25]. Padda IS, Nguyen M. Radioactive iodine therapy. Treasure Island (FL): **2023**.
[26]. Ponto, K.A., Zang, S., Kahaly, G.J., The tale of radioiodine and graves' orbitopathy. *Thyroid*, **2010**, 20(7), 785-793.
[27]. Jung, C.-H., Treatment of graves' disease: Faster remission or longer but safe, that is the question. *Endocrinology and Metabolism*, **2025**, 40(1), 70.
[28]. Biello A, Kinberg EC, Menon G, Wirtz ED. Thyroidectomy. StatPearls. Treasure Island (FL), **2024**.
[29]. Lanzolla, G., Sabini, E. News in graves' orbitopathy: Patients management and treatments. **2023**, 14, 1270467.
[30]. Ugradar, S., Malkhasyan, E., Douglas, R.S., Teprotumumab for the treatment of thyroid eye disease. *Endocrine Reviews*, **2024**, 45(6), 843-857.
[31]. Salvi, M., Vannucchi, G., Currò, N., Campi, I., Covelli, D., Dazzi, D., Simonetta, S., Guastella, C., Pignataro, L., Avignone, S., Efficacy of b-cell targeted therapy with rituximab in patients with active moderate to severe graves' orbitopathy: A randomized controlled study. *The Journal of Clinical Endocrinology & Metabolism*, **2015**, 100(2), 422-431.
[32]. Lane, L.C., Cheetham, T.D., Perros, P., Pearce, S.H., New therapeutic horizons for graves' hyperthyroidism. *Endocrine Reviews*, **2020**, 41(6), 873-884.
[33]. Furmaniak, J., Sanders, J., Sanders, P., Li, Y., Rees Smith, B., Tsh receptor specific monoclonal autoantibody k1-70tm targeting of the tsh receptor in subjects with graves' disease and graves' orbitopathy—results from a phase i clinical trial. *Clinical endocrinology*, **2022**, 96(6), 878-887.
[34]. Mozzi, A., Pontremoli, C., Sironi, M., Genetic susceptibility to infectious diseases: Current status and future perspectives from genome-wide approaches. *Infection, genetics and evolution*, **2018**, 66, 286-307.
[35]. Moledina, M., Damato, E.M., Lee, V., The changing landscape of thyroid eye disease: Current clinical advances and future outlook. *Eye*, **2024**, 38(8), 1425-1437.
[36]. Smith, T.J., Hegedüs, L., Graves' disease. *New England Journal of Medicine*, **2016**, 375(16), 1552-1565.
[37]. Rincon-Arevalo, H., Wiedemann, A., Stefanski, A.-L., Lettau, M., Szelinski, F., Fuchs, S., Frei, A.P., Steinberg, M., Kam-Thong, T., Hatje, K., Deep phenotyping of cd11c+ b cells in systemic autoimmunity and controls. *Frontiers in Immunology*, **2021**, 12, 635615.
[38]. Huber, A., Menconi, F., Corathers, S., Jacobson, E.M., Tomer, Y., Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: From epidemiology to mechanisms. *Endocrine Reviews*, **2008**, 29(6), 697-725.
[39]. Kahaly, G.J., Immunotherapies for thyroid eye disease. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2019**, 26(5), 250-255.
[40]. Ross, D.S., Burch, H.B., Cooper, D.S., Greenlee, M.C., Laurberg, P., Maia, A.L., Rivkees, S.A., Samuels, M., Sosa, J.A., Stan, M.N., 2016 american thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. *Thyroid*, **2016**, 26(10), 1343-1421.
[41]. Abraham, P., Avenell, A., McGeoch, S.C., Clark, L.F., Bevan, J.S., Antithyroid drug regimen for treating graves' hyperthyroidism. *Cochrane Database of Systematic Reviews*, **2010**, (1).
[42]. Cooper, D.S., Antithyroid drugs. *New England Journal of Medicine*, **2005**, 352(9), 905-917.
[43]. Association, A.T., Hyperthyroidism, A.A.o.C.E.T.o., Thyrotoxicosis, O.C.o., Bahn, R.S., Burch, H.B., Cooper, D.S., Garber, J.R., Greenlee, M.C., Klein, I., Laurberg, P., McDougall, I.R., Montori, V.M., Hyperthyroidism and other causes of thyrotoxicosis: Management guidelines of the

american thyroid association and american association of clinical endocrinologists. *Thyroid*, **2011**, 21(6), 593-646.
[44]. Kim MY, Kim JH, Cho MH, Choi YH, Kim SH, Im YJ, Park K, Kang HG, Chae JH, Cheong HI. Urological problems in patients with Menkes disease. *J. Korean Med. Sci*. **2019** ;34:e4.
[45]. Razavi CR, Tufano RP, Russell JO. Completion thyroidectomy: what are the risks of waiting? *Gland Surg*. **2019**; 8(Suppl 2): S112-S120.

How to cite this article:
M.A. Oladosu, M.A. Abah, Chijioke, P. Chigozie, C.U. Ojukwu, G.T. Balogun, C. Uforo, A.M. Busari, F. Nkemehule, A.V. Jemiseye, I.O. Ifeoma, O.A. Oladosu, I.E. Umeh. Autoimmune Mechanisms and Treatment Approaches in Graves' Disease-Induced Hyperthyroidism: A Comprehensive Review. *International Journal of Advanced Biological and Biomedical Research*, 2026, 14(1), 72-89.
DOI: https://doi.org/10.48309/ijabbr.2026.2062050.1616
Link: https://www.ijabbr.com/article_729320.html